Travere Therapeutics, Inc. (TVTX) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 15 Buy, 3 Hold.
The consensus price target is $49.00, representing an upside of 16.3% from the current price $42.13.
Analysts estimate Earnings Per Share (EPS) of $-3.65 and revenue of $0.23B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.08 vs est $-3.65 (missed -11.9%). 2025: actual $-0.56 vs est $-0.34 (missed -67%). Analyst accuracy: 75%.
TVTX Stock — 12-Month Price Forecast
$49.00
▲ +16.31% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Travere Therapeutics, Inc., the price target is $49.00.
The average price target represents a +16.31% change from the last price of $42.13.
TVTX Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to Travere Therapeutics, Inc. in the past 3 months
EPS Estimates — TVTX
75%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$4.08
vs Est –$3.65
▼ 10.6% off
2025
Actual –$0.56
vs Est –$0.34
▼ 40.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TVTX
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.233B
vs Est $0.231B
▲ 0.9% off
2025
Actual $0.491B
vs Est $0.499B
▼ 1.7% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
